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Infectious Mono + Athletics
• Infectious mono incidence rate among young adults = 1-3%
• Incubation period = 30-50 days
• Symptoms typically begin as fever, malaise, and headache
▫ Pharyngitis develops in 80% of those affected
▫ Splenomegaly occurs in 50-100%

• Characteristic exam findings:
▫
▫
▫
▫

Posterior cervical lymphadenopathy
Tonsillar enlargement or exudate
Palatal petechiae
Splenic enlargement

Splenic Rupture
• Rare complication: occurs in 0.1 – 0.2% of cases
• Can occur spontaneously, or as a result of Valsalva or trauma
• Most cases occur in the first three weeks of illness
▫ Cases of splenic rupture have been reported up to 7 weeks following disease
onset

• Myths and misconceptions
▫ Splenic ultrasound has not been validated to be helpful in the assessment of
splenomegaly
 In a study of baseline splenic size in 631 healthy athletes, 7% met the criteria for
splenomegaly

▫ Physical exam is unhelpful in determining splenic size
 Combined palpation and percussion to assess splenomegaly has sensitivity of 46% and
specificity of 97%

Public Health Costs
• Splenic rupture is due to trauma in 86% of cases
▫ 14% occur spontaneously

• EBV infection associated with development of malignancies later in life
including:
▫ Nasopharyngeal carcinoma
▫ Burkitt lymphoma
 85% of Burkitt lymphomas in Africa are EBV positive

▫ Hodgkin lymphoma
 40% in developed countries and 80% in developing countries are EBV positive

Community Perspective
• On return to play implementation:
“I follow the following framework. I keep people out of all athletic activities for
three weeks from the onset of symptoms. To determine the onset of symptoms
I take a careful history to figure out when they started feeling poorly. If there is
ambiguity, I err on the more cautious date of onset. After three weeks I allow
individuals to return to noncontact sports activities. I hold off on adding contact
sports and higher level resistance training until the four-week mark. At four
weeks most individuals are back to full unrestricted participation in their sport.”
Dr. Matthew Lunser
UVM Team Physician

Community Perspective
• On the ambiguity of date of onset, and the challenges of convincing
patients who may already have resumed athletic participation when it
was not safe to do so:
“You have to balance textbook physiology with real life
pragmatism.”
Wayne Warnkan, MD
CHCB Physician

Intervention and Methodology
• Family physicians are often the first to evaluate athletes with suspected
infectious mono, thus clear, universal guidelines for determining return to
play are essential
• Intervention: develop pictorial representation of current return to play
guidelines for athletes with infectious mono

▫ Highlight indications for preventing return to play
▫ Acknowledge areas of ambiguity in diagnosis
▫ Provide evidence-based recommendations to help prevent unnecessary testing

• Ensure dissemination of information to both physicians and coaches to avoid
premature return to play
▫ Due to delay in diagnosis, including description of signs and symptoms of
infectious mono ensures athletes do not resume activities with possible
splenomegaly

Results
• Staged diagram indicating parameters
to be met for progressive return to play
▫ List of symptoms of infectious mono
such that if an athlete presents with
these consideration should be given to
restricting play
▫ Suggestions for decision making when
actual timing of infection onset is
unclear

• Description of symptoms of splenic
rupture indicating immediate
emergency evaluation

Evaluation and Effectiveness of Limitations
• Main benefit is in saving provider time
▫ Consolidating the information and making it more accessible saves the provider
an extensive literature search
▫ Incidence of splenic rupture is so low that rupture itself would not be an effective
outcome to measure

• Diagnostic ambiguity regarding date of onset of illness will persist, but trend
toward assuming shorter length of infection will protect athletes given peak
of splenomegaly occurs ~3 weeks post-infection
• Predicted increased patient satisfaction if criteria for return to play is made
clear from onset
▫ Athlete may still be playing sport at time of diagnosis, thus having clear
framework in place can prevent distress over taking leave of absence from activity

Recommendations for Future Interventions
• Serial ultrasounds to measure arc of change of athletes’ spleens during mono
infection

▫ While studies estimate splenomegaly develops in 50-100% of cases of infectious
mono, none have looked at the degree of change from baseline spleen size and
time course of regression
▫ Current recommendations advise against splenic imaging due to lack of baseline
against which to compare
▫ This information would be helpful in providing a more accurate window of time in
which contact sports should be absolutely avoided

• Development of EBV vaccine

▫ Current efforts have been focusing on gp350, which is highly conserved among
EBV strains
▫ EBV infection linked to development of nasopharyngeal carcinoma and Hodgkin
lymphoma, thus a vaccine preventing these outcomes is highly desirable
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